Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€13.50

€13.50

0.780%
0.105
0.780%
-
 
11:18 / Tradegate WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Novocure Ltd Stock

Novocure Ltd gained 0.780% compared to yesterday.
For the coming years our community has positive and negative things to say abot the Novocure Ltd stock. Criterium "Shareholder structure" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.

Pros and Cons of Novocure Ltd in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novocure Ltd vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novocure Ltd 0.780% 7.378% -10.971% -75.204% -6.200% -87.619% -
Ironwood Pharmaceuticals 2.600% -3.049% -42.391% -20.785% -23.558% -11.667% -31.701%
Iovance Biotherapeutics Inc. 0.810% -4.442% -19.187% 128.293% 66.688% -47.104% -
Fibrogen Inc. -2.460% 3.670% 16.495% -86.622% 162.791% -91.654% -

News

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO


Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3)

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most